Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENABLE-Hip: Rivaroxaban Duration after Hip Arthroplasty
NCT06611319Phase 3Recruiting
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in venous thromboembolism (VTE) (2 arms). Primary endpoint: Rate of acute symptomatic or fatal Venous Thromboembolism at 90 days. Started Nov 2024; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06611319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611319.